Disclosed are mammalian neuronal cells expressing alpha synuclein as well as methods of screening to identify compounds that decrease toxicity induced by alpha synuclein expression. Compounds identified by such screens can be used to treat or prevent synucleinopathies such as Parkinson's disease, familial Parkinson's disease, Lewy body disease, the Lewy body variant of Alzheimer's disease, dementia with Lewy bodies, multiple system atrophy, or the Parkinsonism-dementia complex of Guam.

 
Web www.patentalert.com

< Alpha-Keto Peracids and Methods For Producing and Using the Same

< THERAPEUTING COMPOSITIONS COMPRISING AN RNAI AGENT AND A NEUROTROPHIC FACTOR AND METHODS OF USE THEREOF

> FLUORESCENT MOUSE MODEL

> Diagnostic system for selecting nutrition and pharmacological products for animals

~ 00607